With the breakthroughs achieved of programmed death-1 (PD-1)/PD-L1 inhibitors monotherapy as first-line and second-line treatment in advanced non-small cell lung cancer (NSCLC), the treatment strategy is gradually evolving and optimizing. Immune combination therapy expands the benefit population and improves the curative effect. A series of randomized phase III trials are ongoing. In this review, we discuss the prospect and current situation of immune checkpoint inhibitors in first-line treatment in advanced NSCLC patients.
随着程序性凋亡因子1受体（programmed death-1, PD-1）及其配体（PD-L1）抑制剂单药治疗在晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）的二线和一线治疗中相继取得突破性进展，晚期NSCLC的诊治策略正在逐渐发生演变和优化。免疫联合治疗扩大受益人群、提高疗效，目前已经在一线治疗领域取得初步结果，有多项III期随机对照研究正在进行中。本文将对免疫检查点抑制剂在晚期NSCLC一线治疗中的现状和前景进行综述。.